Compare ING Groep NV (ING) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Inovio Pharmaceuticals Inc — how do they compare? ING Groep NV trades at $33.36 (market cap $93.76B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: ING Groep NV is far larger — about 835.7× Inovio Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.95% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| ING | INO | |
|---|---|---|
Market Cap | $93.76B | $112.19M |
Volume | 4,620,220 | 3,201,278 |
Sector | Financials | Health |
52-Week High | $37.27 | $2.65 |
52-Week Low | $23.66 | $0.66 |
Typical Hold Time | 94 Days | 43 Days |
Enterprise Value | $236.48B | $83.51M |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.37, down 1.62% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue for 2025 reached $22.90 billion, with a net income margin of 28.34%, though cash flow trends show persistent net outflows. Analyst consensus is bullish with 11 buy ratings and no sell recommendations.
The outlook for ING is supported by raised ROE targets and organic growth initiatives, but risks include negative cash flows and regulatory scrutiny. The stock offers value with a P/E of 12.86 and dividend yield, yet investors face headwinds from operational cash burn and macroeconomic sensitivity.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
